Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.79
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.73
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
PBEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (4)
- Newszacks.com·6h ago·Positive
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
View source ↗ - Newszacks.com·1d ago·Neutral
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
View source ↗ - Newszacks.com·62d ago·Positive
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.
View source ↗ - Newszacks.com·63d ago·Neutral
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
View source ↗
Congress trades
No disclosed congressional trades in PBE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.